Kymera Therapeutics (KYMR) Net Cash Flow Growth (3y) (2022 - 2026)
Kymera Therapeutics (KYMR) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - | -126.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126.90% |
| Dec 31, 2025 | 68.66% |
| Sep 30, 2025 | -69.04% |
| Jun 30, 2025 | 78.57% |
| Mar 31, 2025 | -28.57% |
| Dec 31, 2024 | 27.89% |
| Sep 30, 2024 | -15.72% |
| Jun 30, 2024 | -41.18% |
| Mar 31, 2024 | -40.00% |
| Dec 31, 2023 | 47.61% |
| Sep 30, 2023 | 86.55% |
| Jun 30, 2023 | 26.66% |
| Mar 31, 2023 | -34.21% |
| Dec 31, 2022 | -47.48% |